Search
Deborah Peter Lehmann Richmond AO, MBBS, MSc MBBS MRCP(UK) FRACP Honorary Emeritus Fellow Head, Vaccine Trials Group Honorary Emeritus Fellow Head,
Deborah Lehmann AO, MBBS, MSc Honorary Emeritus Fellow Honorary Emeritus Fellow Clinical Associate Professor Deborah Lehmann is a medical
Otitis media (OM) is a significant health concern, particularly among Aboriginal and/or Torres Strait Islander children who experience one of the highest rates of OM globally. This study aimed to evaluate the use and differences of wideband absorbance at ambient pressure (WBA) among urban Aboriginal and/or Torres Strait Islander and non-Aboriginal children with suspected OM based on standard tympanometry.
The introduction of universal newborn hearing screening has allowed for early identification and diagnosis of children with severe-profound hearing loss. This study aims to provide the first Western Australian perspective on the surgical feasibility and safety of cochlear implantation before 12 months of age.
As the frequency of eating out-of-home among Australian families increases, concerns have arisen regarding the nutritional quality of Kids' Menus. This study investigated the views of food business owners and managers on Kids' Menus at sit-down venues, specifically factors influencing the choice of meals offered on Kids' Menus and potential initiatives for enhancing the nutritional quality of these menus.
This study sought to determine the prevalence of Developmental Language Disorder (DLD) in Australian school-aged children and associated potential risk factors for DLD at 10 years.
Australian First Nations children are at very high risk of early, recurrent, and persistent bacterial otitis media and respiratory tract infection. With the PREVIX randomised controlled trials, we aimed to evaluate the immunogenicity of novel pneumococcal conjugate vaccine (PCV) schedules.
Pneumonia is a leading cause of childhood mortality with Streptococcus pneumoniae a major contributor. Pneumococcal conjugate vaccines (PCVs) have been introduced into immunisation programs in many low- to middle-income countries yet there is a paucity of data evaluating the effectiveness in these settings. We assess the effectiveness of 13-valent PCV against hypoxic pneumonia, hospitalisation and other clinical endpoints in children <5 years living in Eastern Highlands Province, Papua New Guinea).
To assess the degree to which timely audiological assessment of congenital hearing loss is achieved at our institution - Perth Children's Hospital, Western Australia, and to review cases which breached this timeframe in order to address barriers to timely assessment. The benchmark used to determine timely assessment is that set out by The Joint Committee on Infant Hearing (JCIH) in which diagnostic audiological testing occurs by three months of age for those who do not pass newborn hearing screening.
Pneumococcal disease outbreaks of vaccine preventable serotype 4 sequence type (ST)801 in shipyards have been reported in several countries. We aimed to use genomics to establish any international links between them.